Elanco Animal Health Incorporated Accumulated Other Comprehensive Income
Elanco Animal Health Incorporated (ELAN) had Accumulated Other Comprehensive Income of -$219.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$219.00M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$233.00M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$141.00M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$199.00M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$219.00M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$233.00M 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$141.00M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$199.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$192.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$583.00M 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$771.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$339.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$542.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$465.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$266.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$482.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$281.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$310.00M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$392.00M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$1.01B 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$649.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$186.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$209.00M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$146.00M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $65.00M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$102.00M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $303.00M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$121.80M 10-Q · filed 2020-11-06 |
| 2020-06-30 | -$214.80M 10-Q · filed 2020-07-30 |
| 2020-03-31 | -$242.60M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$173.70M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$252.50M 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$214.80M 10-Q · filed 2019-08-13 |
| 2019-03-31 | -$250.40M 10-Q · filed 2019-05-14 |
| 2018-12-31 | -$222.20M 10-K · filed 2020-02-28 |
| 2018-09-30 | -$210.30M 10-Q · filed 2018-11-08 |
| 2017-12-31 | -$256.60M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |